Difference between revisions of "Momelotinib (Ojjaara)"
Jump to navigation
Jump to search
m (Jwarner moved page Momelotinib to Momelotinib (CYT387)) |
m |
||
| Line 1: | Line 1: | ||
| − | [[Category: | + | ==Mechanism of action== |
| + | JAK1/2 inhibitor | ||
| + | |||
| + | ==Preliminary data== | ||
| + | ===[[Myelofibrosis]]=== | ||
| + | # Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. [http://www.ncbi.nlm.nih.gov/pubmed/23459451 PubMed] | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | |||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:JAK inhibitors]] | [[Category:JAK inhibitors]] | ||
| + | |||
| + | [[Category:Myelofibrosis medications]] | ||
| + | |||
| + | [[Category:Investigational]] | ||
Revision as of 14:17, 26 November 2014
Mechanism of action
JAK1/2 inhibitor
Preliminary data
Myelofibrosis
- Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. PubMed